In the last trading session, 1.98 million Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) shares changed hands as the company’s beta touched 1.76. With the company’s per share price at $2.22 changed hands at -$0.1 or -4.09% during last session, the market valuation stood at $158.57M. ZNTL’s last price was a discount, traded about -713.96% off its 52-week high of $18.07. The share price had its 52-week low at $1.61, which suggests the last value was 27.48% up since then.
Analysts gave the Zentalis Pharmaceuticals Inc (ZNTL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.00. If we narrow down to specifics, the data shows that 0 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 5 recommended ZNTL as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Zentalis Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.68.
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) trade information
Instantly ZNTL was in red as seen at the end of in last trading. With action -8.44%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -26.57%, with the 5-day performance at -8.44% in the red. However, in the 30-day time frame, Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) is -3.26% down.
The consensus price target for the stock as assigned by Wall Street analysts is 10, meaning bulls need an upside of 77.8% from its current market value. According to analyst projections, ZNTL’s forecast low is 4 with 55 as the target high. To hit the forecast high, the stock’s price needs a -2377.48% plunge from its current level, while the stock would need to soar -80.18% for it to hit the projected low.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at -100.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -50.05%. The 2025 estimates are for Zentalis Pharmaceuticals Inc earnings to increase by 44.92%, but the outlook for the next 5-year period is at 18.52% per year.
ZNTL Dividends
Zentalis Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.
FMR LLC holds the second largest percentage of outstanding shares, with 12.2383% or 8.68 million shares worth $35.49 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Mutual Fund Ser Tr-Eventide Gilead Fund . With 4.95 shares estimated at $11.01 million under it, the former controlled 6.94% of total outstanding shares. On the other hand, Mutual Fund Ser Tr-Eventide Gilead Fund held about 5.03% of the shares, roughly 3.58 shares worth around $7.98 million.
